The nuclear cofactor receptor interacting protein-140 (RIP140) regulates the expression of genes involved in Aβ generation by Blondrath, K et al.
1 
 
The nuclear cofactor Receptor interacting protein-140 (RIP140) regulates the 
expression of genes involved in Aβ generation 
Katrin Blondrath1, Jennifer H. Steel2, Loukia Katsouri1, Miriam Ries1, Malcolm G. Parker2, Mark Christian3* 
and Magdalena Sastre1* 
1. Division of Brain Sciences, Imperial College, London W12 0NN, UK 
2. Institute for Reproductive and Developmental Biology, Imperial College, London W12 0NN, UK 
3. Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, 
Coventry CV4 7AL, UK 
Corresponding author: Magdalena Sastre, Imperial College London, Hammersmith Hospital, Du Cane Road, 
London W12 0NN, phone: +44-2075946673, fax: +44-2075946548, E-mail: m.sastre@imperial.ac.uk; Mark 
Christian, University of Warwick Coventry CV4 7AL, phone: +44-024 76 968585, fax: +44- Email: 
M.Christian@warwick.ac.uk  
 
  
2 
 
Abstract 
The Receptor Interacting Protein 140 (RIP140) is a cofactor for several nuclear receptors and has been involved 
in the regulation of metabolic and inflammatory genes. We hypothesize that RIP140 may also affect Aβ 
generation because it modulates the activity of transcription factors previously implicated in APP processing, 
such as PPARγ. We found that the levels of RIP140 are reduced in AD post-mortem brains compared with 
healthy controls. In addition, in situ hybridization experiments revealed that RIP140 expression is enriched in 
the same brain areas involved in AD pathology, such as cortex and hippocampus. Furthermore, we provide 
evidence using cell lines and genetically modified mice that RIP140 is able to modulate the transcription of 
certain genes involved in AD pathology, such as BACE1 and GSK3. Consequently, we found that RIP140 
overexpression reduced the generation of Aβ in a neuroblastoma cell line by decreasing the transcription of 
BACE1 via a PPARγ-dependent mechanism. The results of this study therefore provide molecular insights 
into common signalling pathways linking metabolic disease with AD. 
Highlights 
*RIP140 is expressed in human cortex and hippocampus and reduced in AD 
*RIP140 knockout and transgenic mice show different expression of genes involved in AD. 
*GSK3 and BACE1 levels are up-regulated in RIP140 knockout mice and reduced by RIP140 overexpression 
in cell lines. 
*RIP140 transient transfection reduces Aβ generation in a neuroblastoma cell line. 
Key words: PPARγ; Alzheimer’s disease; RIP140; BACE1; GSK3; Aβ 
Abbreviations:  AD: Alzheimer’s disease; APP: amyloid precursor protein; BACE1: β-APP cleaving enzyme; 
GSK3: Glycogen synthase kinase 3; PGC1-α: PPARγ coactivator-1α; PPARγ: Peroxisome proliferator-
activated receptor-γ; RIP140: Receptor Interacting Protein 140 
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Introduction 
 
Age-related diseases seem to share common underlying genetic mechanisms and pathways (Johnson et al., 
2015); there is strong evidence for the association between metabolic disorders and neurodegenerative diseases 
with an inflammatory component, such as Alzheimer’s disease (AD) (Sastre et al, 2006a; Sastre et al., 2011). 
Nuclear receptor signalling seems to play an important role linking energy metabolism and inflammatory 
processes (Glass and Oqawa, 2006). The Receptor interacting Protein 140 (RIP140) was identified 15 years 
ago as a cofactor for nuclear receptors and found to function as a co-repressor for a number of nuclear receptors 
that regulate metabolic pathways, including estrogen receptor-related receptors (ERRs), liver X receptor 
(LXR) and Peroxisome proliferator activated receptors (PPARs) (Leonardson et al., 2004; Seth et al, 2007; 
Christian et al., 2006). Subsequently RIP140 was also shown to act as co-activator of NFκB, Sp1 and AhR in 
macrophages thereby stimulating the expression of a number of inflammatory cytokines (Zschiedrich et al., 
2008). Mice lacking RIP140 present some characteristic phenotypes, such as altered energy homeostasis and 
female infertility, which arise from the observation that RIP140 plays an essential role for ovulation (White et 
al., 2000). The generation of RIP140 deficient mice revealed that RIP140 is involved in glucose and lipid 
metabolism in adipocytes, muscle and liver tissue, presenting resistance to diet-induced obesity and increased 
clearance and insulin sensitivity (Powelka et al., 2006; Leonardsson et al., 2004; Herzog et al., 2007; Seth et 
al., 2007). Additionally, studies of not only RIP140 knockout but also RIP140 overexpressing transgenic mice 
have demonstrated roles for this cofactor in heart musculature (Fritah et al., 2010), macrophage activation 
(Zschiedrich et al., 2008), mammary gland (Nautiyal et al., 2013) and brain (Duclot et al., 2012). 
The role of RIP140 in the brain is not fully understood. It has been demonstrated that changes in its expression 
have implications on cognition. A study conducted in the RIP140 knockout mice demonstrated that these mice 
suffer from memory and learning impairments and show an increased response to stress in comparison to wild 
type mice (Duclot et al., 2012). In addition, RIP140 levels seem to be highly expressed during 
neurodevelopmental stages and reduced during aging (Ghosh S, Thakur MK, 2008; Yuan et al, 2012; Katsouri 
et al., 2012). Interestingly, it was recently reported that in neurons, RIP140 contributes to a rapid suppression 
of the ER stress response and therefore provides protection against neuronal death (Feng et al., 2014). 
Importantly, RIP140 is a prominent cofactor for PPARγ, and we have previously reported that PPARγ 
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activation, such as by treatment with TZDs and certain NSAIDs, reduces Aβ in vitro and in animal models of 
AD by affecting BACE1 transcription (Heneka et al., 2005; Sastre et al, 2003, 2006b). 
We hypothesize then that RIP140 affects Aβ generation and/or degradation and therefore may have a role in 
the progression of AD. In this study, we investigated the relevance of RIP140 in AD using cell culture models 
as well as genetically modified mice. The results of this work provide molecular insights into the function of 
factors linking metabolic disease with AD and may offer opportunities for therapeutic intervention. 
Materials and Methods 
Human postmortem samples 
Human brains were obtained from routine autopsies at the Huddinge Brain Bank in accordance with the laws 
and the permission of the ethical committee.  The control group included frontal-cortex from subjects who 
died either of non-neurological diseases or traffic accidents and had no history of long-term illness or dementia 
(76yrs ±6: 4F, 2M). The sporadic AD group included the frontal-cortex samples from patients with clinically 
and pathologically confirmed AD (81yrs ±2: 5F, 2M).  The frozen tissue was crudely fractionated to give a 
nuclear, membrane and cytosolic fraction.  Samples were kept at -80°C until used. 
Animals 
For this study RIP140 knockout (8 males and 3 females) of 9 months of age and RIP140 transgenic mice (5 
male and 7 females) of 5 months of age and their corresponding wild-type littermates were used. This number 
of animals was used to allow enough statistical power was calculated according to our previous experience 
(Sastre et al., 2006). We confirmed this number is appropriate using InVivoStat, an R-based statistical package. 
Generation of the RIP140 knock out line was performed by homologous recombination in embryonic stem 
cells, replacing the RIP140 gene with a lacZ-neofusion gene cassette (IRESβGEO), containing a ribosomal 
entry site, as previously described by White et al., in 2000. Mice used in this study had been backcrossed eight 
generations to C57BL/6J background.  
RIP140 transgenic mice were generated by inserting human RIP140 (hRIP140; NRIP1 – Human Gene 
Nomenclature Database) in FVB/N background using a pCAGGS-hRIP construct (Fritah et al., 2010; Nautiyal 
et al., 2013). FVB/N wild-type (WT) littermates were used as controls.  
Animals were maintained under standard conditions, with controlled light and temperature, and fed a chow 
diet ad libitum. Animals were anesthetized with sodium pentobarbital in a designed area in the morning and 
transcardially perfused with ice-cold phosphate-buffered saline (PBS) (0.1 M, pH 7.4). Brains were rapidly 
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removed, and the right hemisphere was immersion fixed in 4% paraformaldehyde in PBS (0.1 M, pH 7.4) for 
48 hours and then cryoprotected in 20% sucrose in PBS (0.1 M, pH 7.4). The left hemispheres were dissected, 
snap frozen, and stored at -80° C until protein isolation. 
All animal experiments conformed to the British Home Office Regulations (Animal Scientific Procedures Act 
1986).  
Cell lines, cell culture, and transient transfection.  
Mouse neuroblastoma N2a cells stably transfected with AβPP695 containing the Swedish mutation (AβPPsw, 
K595N/M596L) were obtained from G. Thinakaran (University of Chicago, Chicago, IL) and were cultured 
in 60% DMEM with 40% Opti-MEM and 5% fetal bovine serum supplemented with 0.2 mg/ml G418. Cells 
were incubated at 37°C in a 5% CO2 atmosphere. Transfections were performed using Lipofectamine 2000 
(Invitrogen) or FuGene (Roche) as described previously (Sastre et al., 2006) with 10 μg RIP140 or RIP140 
shRNA, mouse PPARγ cDNA (from Dr. Ron Evans, The Salk Institute for Biological Studies, San Diego, 
CA). For RIP140 siRNA (Genepharma), PPARγ siRNA and BACE1 siRNA (both from Dharmacon) we used 
20µM per 6 well-plate. As controls we used empty plasmid and control siRNA. Cells were treated with 10-20 
μM Pioglitazone (Tocris Bioscience) or DMSO overnight. 48h after transfection, cells were harvested. 
Transfection efficiency was determined by Western blot, immunofluorescence or qPCR. 
Western blotting 
Cell lysates and brain homogenates were extracted with radioimmunoprecipitation assay buffer (1% Triton X-
100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 150 mM NaCl, and 50 mM Tris-HCl, pH 
7.2) supplemented with Roche Complete protease inhibitor and phosphatase inhibitor (PhosSTOP) cocktails. 
Equal amounts of protein (20-100 μg) samples were separated in SDS-polyacrylamide gel electrophoresis 
(PAGE) gels, followed by immunoblotting with primary antibodies (listed in supporting information), and 
detected with horseradish peroxidase conjugated secondary antibody in 5% non-fat dried milk in Tris-buffered 
saline with 0.05% Tween-20. Membranes were developed using ECL reagents (GE Amersham, UK) and using 
Hyperfilm ECL audioradiography film in an automated developer (Konica, SRX 101A). The intensity of the 
bands was quantified by densitometry using Image J software (National Institutes of Health) and normalized 
to β-Actin. 
Determination of secreted APPα ectodomain and Aβ.  
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Secreted APP-α (sAPPα) and Aβ in the medium were measured by Western blotting after separation by 4-12% 
NuPAGE gels (Invitrogen) followed by transfer to nitrocellulose membranes and immunodetection with 
antibody 6E10 and the ECL system (Amersham Biosciences, Freiburg, Germany). The protein bands were 
scanned and quantified (NIH Image J analysis program) and results were corrected according to the protein 
concentration in cell lysates.  
Determination of β-secretase activity.  
The enzymatic activity of β-secretase was measured by a fluorimetric reaction (Abcam). The assay uses a 
secretase-specific peptide conjugated to two reporter molecules, EDANS and DABCYL. In the uncleaved 
form, the fluorescent signal from EDANS is quenched by the physical proximity of the DABCYL moiety. 
Cleavage of the peptide by β-secretase physically separates EDANS and DABCYL allowing for the release of 
a fluorescent signal. N2aSw cells were resuspended in 200μl of the “Extraction Buffer”. 50μl of the sample 
was incubated with 50μl of the 2X “Reaction Buffer” and 3μl of substrate at 37ºC for 2hrs with mild shaking 
in the dark. The fluorescence was measured using a fluorimeter (Spectramax Gemini) using approximately 75 
μg of protein lysate per well, with excitation between 335-355nm and emission detection between 495-510nm. 
As positive control we used Active β-secretase and as negative control a β-secretase inhibitor provided by the 
supplier.  
We also analysed the generation of the carboxy-terminus fragments (CTFs) in brain homogenates as 
measurement of secretase’s activity. CTFs were determined by Western blotting after separation of samples in 
4-12% NuPAGE gels (Invitrogen) followed by transfer to nitrocellulose membranes and immunodetection 
with antibody R1-57. The protein bands were scanned and quantified (NIH Image J analysis program) and 
results were normalized to full length APP. 
Immunocytochemistry 
The subcellular localization of RIP140 and APP was detected in N2a cells overexpressing APPsw and RIP140 
grown to 70% confluence on sterilised coverslips. Cells were washed once in sterile 1X PBS and then fixed 
and permeabilized in 100% methanol for 10 mins at -20ºC. The cells were then rehydrated with PBS and 
blocked in 10% bovine serum albumin (BSA) made up in PBS for 10 minutes at RT.  Cells were washed 3X 
in PBS. Primary antibodies were prepared in 1% BSA in PBS. A monoclonal mouse anti RIP140 was used at 
1/500 and full length APP was detected by R1-57 at 1/100.  Cells were incubated with the primary for 1 hour 
at 37ºC in a humid chamber to prevent coverslips from drying out. Secondary Anti-Rabbit Alexa Fluor 488® 
7 
 
(Invitrogen, US) and an anti-mouse Alexa Fluor 594® were used at 1/200 for 1hr at 37C. The coverslips were 
mounted onto glass slides using Vectashield mounting medium with a DAPI counterstain (Vector Laboratories, 
Burlingame,CA) and observed under confocal microscope. 
ELISA 
The levels of human Aβ1-40 and Aβ1-42 in the media of N2asw cells were determined using High Sensitivity 
Human Amyloid β40 and β42 ELISA kit (Millipore). The standard curve ranged 16 pg/mL–500 pg/mL. 
Concentrations were quantified according to the manufacturer’s instructions. 
RNA preparation, reverse transcription-PCR and qPCR  
RNA extraction was performed using Trizol reagent (Sigma) and reverse-transcription quantitative-PCR 
analysis was performed using a 2 step method with an initial RT and subsequent real time cycling on a 
Strategene Mx3000p block cycler. Real time cycling was carried out with the Quantifast® SYBR green 
(Qiagen) and Quantiect® Primer assays (Qiagen) for mouse BACE1. Other primers used to measure mRNA 
levels of other genes are listed in table 1 (Supporting information). All genes were normalized to a 
housekeeping gene, which were in our case was GAPDH. A post melt-curve analysis revealed the absence of 
primer dimmers for all primer sets. For each repeat a calibration curve (100, 10, and 1 ng) was produced for 
each transcript to ascertain the primer set efficiency and the cDNA input. The efficiency is described by the 
equation: E = 10(−1/slope). 
In addition, RT2-Profiler PCR array (Qiagen) was carried out in hippocampal mRNA extracts for analysing 
the expression of a focused panel of genes related to Alzheimer's Disease. The array includes genes that 
contribute to amyloid beta-peptide (Aβ) generation, clearance, and degradation, as well as genes involved in 
amyloid beta-peptide (Aβ) signal transduction leading to neuronal toxicity and inflammation. 
Luciferase Assay.  
The luciferase reporter assay for BACE1 promoter activity was performed according to the instructions of the 
manufacturer (Promega). Briefly, the cells were transfected with 800 ng Luc-plasmid and 2ng CMV-Renilla-
Plasmid (1:400 ratio) for 24 well plate. 48h after transfection the cells were harvested and resuspended in 200 
μl of lysis buffer. Equal amounts of proteins were used for the assay. 
β-Galactosidase staining 
Brains were fixed in 2.5% methanol-free paraformaldehyde during 1 h at 4°C. After three washes in cold 
phosphate buffer saline with 0.2 mM MgCl2, 0.02% NP-40 and 0.01% sodium deoxycholate, tissues were 
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incubated in a LacZ staining solution (10 mM K3Fe(CN)6, 10 mM K4Fe(CN)6, 3H2O and 1.5 mg/ml X-Gal) 
overnight at 37◦C protected from light and postfixed in 4% methanol-free paraformaldehyde. 
In situ hybridization 
An RNA probe for RIP140 exon 1b was transcribed from a cDNA template using a Megascript SP6 or T7 kit 
(Ambion), incorporating digoxigenin-11-UTP (Roche) (Nichol et al, 2006). Sections were deparaffinised, 
rehydrated and then permeabilised by digestion with proteinase K. Sections were fixed in 4% 
paraformaldehyde, washed and air dried before hybridisation. The probe was diluted between 1:50-1:100 with 
hybridisation buffer (50% formamide, 5x SSC, 1x Denhardt's solution, 10% dextran sulphate, and 100 µg/ml 
denatured herring sperm DNA) and 10 µl of diluted probe was applied to each section and incubated in a humid 
chamber overnight at 55°C. RNase pre-treated sections or sections receiving hybridisation buffer only or sense 
probes, were used as negative controls. Following the hybridisation step, the slides were washed to remove 
excess and non-specifically bound riboprobe. For detection of the hybridised probe, slides were incubated with 
an anti-digoxigenin-alkaline phosphatase conjugate (Roche).Alkaline phosphatase-labelled hybrids were 
detected using a solution of 337 µg/ml nitro blue tetrazolium (NBT, Roche), 175 µg/ml 5-bromo-4-chloro-3-
indolyl phosphate (BCIP, Roche) and 1 mM levamisole. Slides were rinsed and mounted in aqueous mountant 
(Glycerol Gelatine, Sigma).  
Statistical Evaluation.  
Data were statistically analyzed by GraphPad Prism 5 by using Student’s t test or ANOVA followed by the 
Newman-Keuls multiple comparison test or the Dunnett post hoc test, depending on whether we were 
comparing different groups with the control group (Dunnett) or whether all pairs of columns were compared 
(Newman-Keuls multiple comparison). 
 
Results 
RIP140 expression is reduced in AD brain 
We have previously reported that the expression of PPARγ and its main co-activator PGC-1α are reduced in 
the brain of AD patients (Sastre et al., 2006; Katsouri et al., 2011). We determined whether the expression of 
RIP140 was altered in AD patients, comparing brain samples from AD patients with age-matched healthy 
control brains. We performed immunoprecipitation/Western blotting experiments with antibody 6D7 against 
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RIP140 in nuclear extracts from frontal cortex from 7 AD cases and 6 controls. The results indicate that RIP140 
expression is reduced in AD patients compared to healthy controls (Fig. 1A).  
Distribution of RIP140 in the mouse brain 
We then explored the localization of RIP140 in the brain. In situ hybridisation was carried out in brain sections 
of a healthy human brain (Fig. 1B) and sagittal sections of wild-type mice, using a probe against exon 1b of 
RIP140. The results show that RIP140 is highly expressed in cortical areas, in particular in the hippocampus, 
frontal cortex as well as in the cerebellum (Fig. 2A). 
Another way to determine the distribution of RIP140 was by performing β-Galactosidase staining to detect 
LacZ gene expression in sections of RIP140 knockout mice. Because RIP140 gene was replaced by the LacZ 
sequence in the generation of RIP140-KO animals, β-galactosidase transcription is driven by the RIP140 
promoter and therefore mirrors the expression of the endogenous RIP140 gene in WT mice. LacZ staining 
confirmed the localisation of the RIP140 gene in cells from hippocampus and cortical areas of the brain 
(Figures 2B and 2C), two areas highly involved in AD pathology. 
RIP140 regulates the expression of genes involved in Alzheimer’s disease 
Because RIP140 is a co-regulator for transcription factors implicated in AD (such as PPARγ and NFκB) and 
is expressed in key regions of the brain associated with the pathology, we performed a qPCR based array 
(Qiagen) specific for genes involved in AD, using mRNA extracts from hippocampal tissue of two male mice 
lacking RIP140 and 2 matching wild- type controls. 
The results illustrated in figure 3A show genes that are up-regulated in RIP140 KO mice (bars with values 
above the baseline) or down-regulated (values below the baseline) in comparison to wild-type expression of 
the gene. Genes of interest that appeared to be up-regulated in RIP140 null mice were ApoA1, Bace1, Bace2, 
Cdk5, Gap43, Igf2 and Mtap2 (green arrows) and genes down-regulated were ApoE, Gsk3β and Ide (red 
arrows). Interestingly, many of these genes seem to be related to the insulin signalling pathway (Fig 3A). 
Additionally, we aimed to confirm these data by qPCR, increasing the number of animals per group, selecting 
the most interesting genes and adding some genes not present on the array but of relevance for AD, such as 
Neprilysin and Mtap1. The results confirmed the up-regulations of genes such as Bace1, Cdk5, Mtap2, and 
Gap43 in RIP140 knockout brains and a reduction in the transcription levels of ApoE, compared to Wild-type 
mice (Fig. 3B). 
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Furthermore, we analysed the expression of the same set of genes in the brains of RIP140 transgenic mice and 
their wild-type littermates. In contrast with the results obtained in the knockout, BACE1, Mtpa1 and Mtap2 
mRNA values appeared reduced in RIP140 transgenics (Fig. 3C) when compared with wild-type mice. No 
significant changes were detected in other genes. 
RIP140 regulates the expression of GSK3 
An interesting gene that was found altered in the mRNA screening of RIP140 knockout brain was GSK3. This 
kinase has been involved in both tau phosphorylation and Aβ generation (Bhat et al., 2004). Two isoforms of 
GSK3 exist, GSK3β and GSK3α and both versions are ubiquitously expressed but partially involved in 
different processes (Jope and Johnson, 2004). GSK3 is negatively regulated by kinases that directly 
phosphorylate a regulatory N-terminal serine of GSK3 [shown as Ser9 (S9) of GSK3b].(Jope and Johnson, 
2004). We assessed the expression of both GSK3 isoforms as well as p-GSK3 by Western blot in the brains of 
RIP140 knockout and transgenic mice. 
p-GSK3β levels were not significantly different between wild-type and RIP140 null and RIP140 transgenic 
mice (Fig. 4A). However, the expression of both GSK3α and GSK3β isoforms were found increased in cortex 
of RIP140 knockout mice (Fig. 4A). In order to know whether GSK3 activity was also altered in the brain of 
RIP140 knockout and transgenic mice, we determined the expression of Axin2. Axin2 is a gene regulated by 
activation of the Wnt/β-catenin pathway, which is modulated by GSK3 (Jho et al., 2002). Our results show a 
marked reduction of Axin2 mRNA in the cortex of RIP140 knockout mice and a non-significant increase in 
the brains of transgenic mice compared with wild-types (Figure 4B). These results are consistent with the 
increases in GSK3 expression found in RIP140 knockout mouse brains. 
To confirm whether RIP140 affected GSK3 expression in neurons in vitro and whether this was mediated 
through a mechanism involving PPARγ, we performed the same experiments in N2asw cells transfected with 
PPARγ siRNA. N2a cells stably expressing APPsw were transfected with human RIP140 cDNA tagged with 
V5. We found a decrease on p-GSK3β levels, probably due to a reduction in the expression of GSK3β in cells 
overexpressing RIP140 (Fig. 4C). However, this effect was not mediated through PPARγ since the values were 
not reversed by PPARγ knockdown (Fig. 4C). A down-regulation of GSK3β mRNA levels by RIP140 
exogenous overexpression was also found when analysed by qPCR (Fig. 4D). The confirmation of the 
efficiency of transfection is shown in figures 5A and 5B, by immunofluorescence experiments and also by 
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Western blot with an antibody against V5. Therefore, RIP140 seems to repress the expression of GSK3 by 
regulating a transcription factor different of PPARγ. 
RIP140 affects Aβ generation by reducing BACE1 transcription 
An additional gene that was found significantly altered in RIP140 knockout brains was BACE1. Therefore, we 
next evaluated the effect of exogenous RIP140 expression on the expression and activity of this enzyme. As 
mentioned previously, BACE1 transcription is regulated by nuclear receptors such as PPARγ or estrogen 
receptors, whose activity is controlled by RIP140. When transfecting a human construct of RIP140 into the 
neuronal N2aSw cell line we demonstrated that its localisation was exclusively nuclear (Fig.5A). Cells were 
also incubated with Pioglitazone (20 μM) during 40h, since it has been described that RIP140 binds to PPARγ 
in ligand activated dependent manner. BACE1 protein expression was reduced by RIP140 overexpression by 
almost 50% (Fig. 5C). Conversely, RIP140 knockdown by transfection of RIP140 siRNA resulted in an 
increase in BACE1 expression (Fig. 5D) and prevented the down-regulation of BACE1 levels by pioglitazone. 
To determine whether BACE1 activity was also decreased by RIP140, a fluorescence enzymatic assay for β-
secretase was performed using a synthetic peptide containing the specific β-cleavage site, showing around 15% 
decrease in β-secretase activity in cells transfected with RIP140 or PPARγ cDNAs (Fig. 5E). 
Changes in BACE1 expression were paralleled with alterations in BACE1 mRNA levels (Fig. 5F). As observed 
above, cells transfected with RIP140 siRNA showed increased BACE1 mRNA levels (Fig. 5F). In addition, 
we examined whether BACE1 promoter activity was modulated by RIP140 using a Firefly luciferase reporter 
gene driven by the rat BACE1 promoter transfected in N2asw cells. We observed a reduction in the activity of 
the BACE1 promoter in cells transfected with RIP140 and an increase with RIP140 knockdown (Fig. 5G).  
In order to determine whether the effects of RIP140 on BACE1 transcription were mediated through activation 
of PPARγ, we performed Western blotting for BACE1 in cells transfected with PPARγ siRNA. The results on 
Figure 5H show that the reduction in the levels of BACE1 following RIP140 transfection were restored to 
control levels after RIP140 exogenous expression in PPARγ knockdown cells. These data suggest that RIP140 
represses BACE1 transcription by acting as a cofactor for PPARγ. 
In line with this, our in vitro results in N2asw cells coincided with in vivo data obtained in brain homogenates 
of RIP140 transgenic mice, which showed a significant reduction of BACE1 expression compared to wild-
type animals (Fig. 5I). Furthermore, we found a strong increase in total CTFs in the knockout brain 
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homogenates compared to wild-type controls (Figure S1A), indicating a reduction in β-secretase activity, with 
no changes in the transgenic mice. 
Because BACE1 is a key enzyme for Aβ generation, we next examined whether RIP140 was able to alter the 
levels of Aβ in N2asw cells. Under these conditions, cells overexpressing RIP140 and simultaneously activated 
with Pioglitazone showed a 24% reduction on secreted Aβ, in particular the Aβ42 subtype (Fig. 6A and 6B). 
This effect was not due to a decrease in full length APP (Fig. 6C) or in the cleavage by α-secretase, as levels 
of soluble APPα were unchanged by the treatment (Fig. 6C). 
Discussion 
Epidemiological studies have indicated a link between metabolic diseases such as type 2 diabetes and 
Alzheimer’s disease (AD), with the risk of incidence 65% higher in individuals with diabetes mellitus than in 
those without (Arvanitakis et al, 2004). The mechanisms mediating these effects are not clear, but it has been 
hypothesized that insulin resistance (IR) and brain glucose deprivation impair brain function. IR and type-2 
diabetes involve a state of chronic inflammation characterized by abnormal cytokine production, increased 
acute-phase reactants and other mediators, and the activation of a network of inflammatory signalling pathways 
(Hotamisligil, 2006), which could lead to higher propensity to develop AD or to exacerbate AD symptoms. 
Both PPARγ and its cofactor RIP140 have been implicated in the control of insulin sensitivity. The role of 
PPARγ is supported by the fact that several familial mutations in PPARγ lead to severe IR and diabetes mellitus 
(Barroso et al, 1998). Furthermore, mice deficient for PPARγ in skeletal muscle have significant whole body 
IR (Hevener et al, 2003). The PPARγPro12Ala polymorphism, which is associated with an increased risk of 
type 2 diabetes (Altshuler et al., 2000), has been found to influence plasma 24S-hydroxycholesterol/cholesterol 
ratios in AD patients (Sauder et al., 2005). In addition, PPARγ activators such as TZDs are widely used to 
increase peripheral insulin sensitivity (Wagstaff and Goa, 2002). These data suggest the possibility of a 
common genetic propensity for AD and IR. The importance of RIP140 in these signalling pathways was 
confirmed by examining the phenotype of RIP140 null mice which store markedly less triglyceride in white 
adipose tissue and exhibit protection from hepatic steatosis, resistance to diet-induced obesity and increased 
clearance and insulin sensitivity (Leonardsson et al., 2004; Powelka et al., 2006).  Whole-body RIP140 
knockout animals are lean and maintain insulin sensitivity, suggesting that RIP140 globally promotes fat 
accumulation and insulin resistance (Leonardsson et al., 2004; Powelka et al., 2006). Therefore, our initial 
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interest was to explore the function of a metabolic modulator such as RIP140 in the brain and whether RIP140 
affected the progression of neurodegenerative diseases like AD.  
In this study we found that indeed RIP140 knockout brains present alterations in the transcription of genes 
linking AD with the insulin pathway, such as GSK3 and IGF2. As indicated previously, RIP140 has been 
found to function as a co-repressor for nuclear receptors that regulate metabolic pathways (Leonardson et al., 
2004; Seth et al, 2007; Christian et al., 2006) but can also act as co-activator for transcription factors regulating 
inflammatory genes and cell proliferation such as NFκB (Zschiedrich et al., 2008; Nautiyal et. al, 2010). We 
found that RIP140 represses BACE1 transcription by a mechanism mediated by PPARγ. The reduction in 
BACE1 transcription observed by overexpression of RIP140 coincides with previous results in cells 
transfected with the transcriptional regulator PGC-1α (Katsouri et al., 2011; Gong et al., 2010; Wang et al 
2013) or with PPARγ cDNA or by incubation with PPARγ agonists (Sastre et al, 2003, 2006b). The specificity 
of the effect of the PPARγ activators on BACE1 was confirmed in PPARγ knockout cells and in N2asw cells 
transfected with PPARγ siRNA, where these drugs did not affect BACE1 transcription (Sastre et al., 2006b). 
Our new data show that pioglitazone did not alter BACE1 expression in cells transfected with RIP140 siRNA 
(Figure 5D), thereby demonstrating that the effect of pioglitazone on BACE1 transcription seems to be 
mediated via RIP140 regulation of PPARγ. Therefore, our results show that RIP140 binds to PPARγ in a 
ligand-activated dependent manner, leading to lower BACE1 transcription and subsequently reduced Aβ 
generation (see schematic summary in Fig. S1B). 
Another important gene regulated by RIP140 is GSK3. GSK3 activity is increased in the frontal cortex of AD 
patients and its expression is up-regulated in the hippocampus (Blalock et al. 2004). It co-localises with 
degenerating neurites and NFTs (Yamaguchi et al. 1996; Pei et al. 1997) and active GSK3 appears in neurons 
with pre-tangle changes (Pei et al. 1999). GSK3 is not only important for regulating Tau pathology but also 
Aβ generation; recently our group demonstrated that GSK3 inhibition promotes lysosomal biogenesis and 
autophagic degradation of the APP (Parr et al., 2012) and the transcription of BACE1 through the Wnt/β-
catenin pathway (Parr et al., 2015). 
We found that the frontal cortex of RIP140 knockout mice expressed elevated levels of GSK3-α and GSK3-β 
compared to wild-type mice and reduced transcription of the Wnt target gene Axin2. Conversely, in vitro 
experiments carried out in N2asw cells seem to indicate that RIP140 overexpression reduces the levels of 
GSK3 mRNA, therefore indicating that RIP140 represses its transcription. It would be thus interesting to 
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determine whether the GSK3 promoter contains consensus binding sites for transcription factors regulated by 
RIP140. This effect does not seem to be mediated through PPARγ, since treatment of N2asw cells with PPARγ 
activators such as pioglitazone did not affect GSK3 expression (data do not shown) and PPARγ knockdown 
did not reverse GSK3 down-regulation by RIP140. It is worth noting that RIP140 could modulate 
transcriptional initiation at regulated promoters by a variety of mechanisms, including histone acetylation and 
chromatin remodelling (Kiskinis et al, 2007; Katsouri et al., 2012), and would be attractive to investigate in 
the future if this is the case for GSK3 regulation. 
An alternative interpretation for the alterations on GSK3 expression may be found in the effects of the insulin 
signalling pathway on GSK3. Impairment of insulin signalling in the brain has been linked to tau 
phosphorylation. As mentioned before, RIP140 null mice exhibit high insulin sensitivity resulting in lower 
insulin plasma level due to their lower fat body content and higher insulin degradation. Insulin signalling 
activates the PI13-kinase which activates Akt8 a factor known to phosphorylate GSK3α and β at two serine 
residues (Saltiel and Kahn 2001; Lizcano and Alessi 2002). This serine phosphorylation leads to prevention of 
the enzymatic activity of GSK3. In fact, neuronal insulin receptor knockout mice present reduced pGSK3 
levels (which is less active) and increased tau hyperphosphorylation (Schubert et al., 2004). This could also 
mean that regulations of GSK3 expression in our mouse model could be consequence of whole body RIP140 
knockout on the insulin pathway rather than a transcriptional regulatory effect of RIP140 on GSK3 in the brain.  
Conclusions 
Overall, our study provides evidence for the protective effects of RIP140 in AD. The observation of reduced 
RIP140 levels in AD patients further support RIP140 down-regulation favouring disease progression. 
Therefore, therapies developed towards increasing RIP140 expression in the brain would be effective for 
treating AD. RIP140 expression could be pharmacologically manipulated by activating a number of nuclear 
receptors including steroids/retinoids or alternatively, by delivering its cDNA into the brain using gene therapy. 
In line with this, recently we have successfully administered PGC1α via lentiviral injection, another PPARγ 
activator, in the cortex and hippocampus of transgenic APP23 mice (Katsouri et al, 2015 unpublished 
observations). 
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Figure legends 
Figure 1. RIP140 is decreased in AD post-mortem brains. A, Representative Western blot and quantification 
of RIP140 levels. β-actin was used as control for protein loading, n=6-7 subjects per group. Values are 
expressed as mean±SEM; *P<0.05, Student’s t test. B, In situ hybridisation in cortex, using specific primer 
designed for RIP140 transcript show specific RIP140 labelling in human brain. 
Figure 2. Distribution of RIP140 in the mouse brain. A, In situ hybridisation, using specific primer designed 
for RIP140 transcript show specific RIP140 labelling in the brain, especially within the hippocampus and 
frontal cortex areas. The cerebellum and caudate are also enriched in RIP140. B, β-Galactosidase staining 
indicates LacZ expression in the RIP140 RIP140 null brain, showing high levels of expression in the dentate 
gyrus and cerebral cortex. C, In situ hybridization and β-Galactosidase in the same section of the cortex, shows 
co-localization in the same cells. Scale bars= 100 μm. 
Figure 3. RIP140 regulates the expression of genes involved in Alzheimer’s disease. A, Results obtained from 
RT² Profiler PCR array focused on genes involved in AD was used to compare the profile of hippocampal 
mRNA samples of 2 months old RIP140 knockout and of wild-type mice. Differences are expressed in fold 
change to the baseline 1. Green arrows highlight genes exhibiting up-regulation. Red arrows show genes down-
regulated in RIP140 knockout mice. B, mRNA hippocampal levels of the selected genes exhibiting up- and 
down-regulation in the screening shown above were further analysed in a larger number of RIP140 knockout 
mice (9 months old), showing significant differences compared with wild-type mice (n=4-6 animals per group). 
C, The same set of genes were analysed in mRNA extracts from cortex of 5 m.o. RIP140 transgenic mice, 
showing opposite effects (n=3-5 animals per group). Values shown in graphs represent the mean value ±SEM 
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and are expressed as a fold change in comparison to the normalized wild-type control. Statistical analysis 
included student’s t-test *P<0.05, **P<0.01, ***P<001.  
Figure 4. RIP140 regulates GSK3 expression. A, Representative Western blots and quantification of GSK3 
subtypes (α and β) and phosphorylated S9 GSK3 protein levels in cortex of RIP140 knockout and transgenic 
mice with their respective controls (n=4-5 animals per group). B, Quantification of Axin2 mRNA levels in 
cortex of RIP140 knockout and transgenic mice with their respective controls (n=4-5 animals per group). C, 
Representative Western blot and quantification of GSK3α and β as well as phosphorylated S9 GSK3 protein 
expression in N2asw cells transfected with RIP140 and/or PPARγ siRNA show that the effect is independent 
on PPARγ expression (n=10-12 samples per group). D, Quantification of GSK3β mRNA expression in N2asw 
cells overexpressing RIP140 cDNA with or without 20 μM Pioglitazone (pio). Values shown in graphs 
represent the mean value ±SEM and are expressed as a percentage change in comparison to the normalized 
wild-type control or fold change of control. Statistical analysis included student’s t-test or one-way ANOVA 
followed by Dunnett's or Newman-Keuls Multiple Comparison Test. *P<0.05, **P<0.01. 
Figure 5. RIP140 reduces BACE1 expression. A, Immunofluorescence labelling using the 6D7 antibody 
against RIP140 protein (green) shows its cellular localisation, strictly restricted to the cell nucleus. The 6E10 
antibody was used to detect full length APP (red), showing its distribution in plasma membrane and cytoplasm. 
DAPI (blue) was used to stain the nucleus of the cells. B, Representative Western blot showing the efficiency 
of transfection with RIP140 cDNA using antibody against V5. C, Representative Western blots and 
quantification of BACE1 in N2asw cells shows a reduction in cells expressing RIP140 with vehicle or 
incubated with 20 μM pioglitazone (n=4-5 samples per group). D, Representative Western blots and 
quantification of BACE1 in N2asw cells shows a reduction in cells incubated with 10 μM pioglitazone and an 
increase in cells transfected with RIP140 siRNA (n=9-12 samples per group). E, Quantification of enzymatic 
β-secretase activity using a fluorimetric assay shows a reduction in N2asw cells transfected with RIP140 or 
PPARγ cDNAs (n=4 samples per group). F, Quantification of BACE1 mRNA in N2asw cells transfected with 
RIP140 cDNA or with RIP140 siRNA shows the opposite effects of both treatments (n=6-9 samples per group). 
G, Luciferase activities of a 1.5-kb BACE1 promoter/luciferase reporter construct transfected in N2a cells 
shows similar changes that were observed in BACE1 mRNA with the same conditions (n=5-8 samples per 
group). H, Representative Western blot and quantification of BACE1 expression in N2asw transfected with 
siRNA for PPARγ shows that the effect of RIP140 is reversed when PPARγ is knock-down (n=8 samples per 
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group). I, Representative Western blot and quantification of BACE1 in the cortex shows a reduction in RIP140 
transgenic mice (n=3-4 animals per group). Values shown in graphs represent the mean value ±SEM and are 
expressed as a percentage change in comparison to the normalized wild-type control or fold change of control. 
Statistical analysis included student’s t-test or one-way ANOVA followed by Dunnett’s or Newman-Keuls 
Multiple Comparison Test *P<0.05, **P<0.01, ***P<001. 
Figure 6. RIP140 exogenous expression reduces Aβ levels in N2asw cells. A, Representative Western blot and 
quantification of Aβ in N2asw cells with 6E10 antibody shows reduced expression with the combination of 
RIP140 and 20 μM pioglitazone (pio), (n=6-7 samples per group). B, Quantification of Aβ40 and Aβ42 
subtypes by ELISA shows also a reduction of Aβ42 in the same conditions (n=3-4 samples per group). C, 
Representative Western blots and quantification of full length APP and soluble APPα in the same cells show 
no significant differences with the treatment (n=5-11 samples per group). Values shown in graphs represent 
the mean value ±SEM and are expressed as a percentage change in comparison to the normalized wild-type 
control. Statistical analysis included one-way ANOVA followed by Dunnett's or Newman-Keuls Multiple 
Comparison Test *P<0.05. 
 
